Why MorphoSys puts so much weight behind Monjuvi in lymphoma care

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 09:44. Details in the imprint.

Monjuvi sits in the infusion bag, clear and almost inconspicuous, while patients with relapsed or refractory diffuse large B-cell lymphoma hope for another therapeutic chance. The antibody from MorphoSys and partner Incyte is meant to make a brutal disease phase a little more predictable.

What Monjuvi is designed to do

At its core, Monjuvi is a humanized anti-CD19 monoclonal antibody, administered in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma who cannot undergo autologous stem cell transplant.

In the US, it was granted accelerated approval by the FDA in 2020 based on overall response rate data, putting it into a niche where patients otherwise faced limited realistic options.

How the therapy is given

Monjuvi is not a quick pill but an intravenous infusion, usually given in 28-day cycles alongside oral lenalidomide, with intensive dosing at the start and gradually fewer infusions over time.

Patients typically spend several hours per visit in the infusion chair, with nurses watching closely for infusion-related reactions, changes in blood counts, or signs of infection.

Efficacy data in a difficult setting

The key L-MIND study that underpinned the initial approval reported an overall response rate of around 55 percent in heavily pretreated DLBCL patients, with complete responses in roughly 18 percent.

Median duration of response reached about 21.7 months in the study, a respectable figure in a late-line setting where many treatments lose effect quickly.

Safety profile and everyday trade-offs

On the downside, Monjuvi plus lenalidomide comes with a predictable but tough side-effect profile, including neutropenia, infections, fatigue, and anemia, which often require dose modifications or growth factor support.

For patients, that can mean frequent blood tests, occasional antibiotics, and a constant balancing act between keeping the lymphoma under control and protecting a vulnerable immune system.

Position vs other lymphoma options

Since its launch, the competitive field has tightened, with CAR-T cell therapies, other anti-CD19 agents, and bispecific antibodies expanding choice in relapsed DLBCL.

Monjuvi tends to be considered where CAR-T is not feasible, for example in older or frail patients, or where logistics and costs of cell therapy are prohibitive.

Regulatory and commercial footprint

In the US, Monjuvi is co-commercialized with Incyte under a profit-sharing agreement, while the product is known as Minjuvi in the European Union, where it has a conditional marketing authorization in a similar patient group.

Pricing in high-income markets is in the range typical for modern oncology antibodies, with reimbursement decisions and local treatment guidelines strongly influencing real-world uptake.

MorphoSys context and stock reference

For MorphoSys, Monjuvi has been a strategic cornerstone that helped shift the company from a pure licensing model to a more integrated oncology player alongside its later acquisition by sector peer institutions.

Shares of MorphoSys (DE0006632003) last traded on Xetra at a low-single-digit euro price level in 2026, reflecting both the challenges and optionality in its oncology portfolio.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.